GM-CSF receptor Inhibitors
1 drugsAbout GM-CSF receptor
The Granulocyte-Macrophage Colony-Stimulating Factor receptor (GM-CSF receptor) is a cell surface receptor mediating the effects of GM-CSF, a cytokine stimulating immune cell production and function. Its role in hematopoiesis and immune regulation makes it a relevant target for therapeutic intervention.
Currently, there is no genetic evidence directly linking the GM-CSF receptor to specific diseases. Targeting the GM-CSF receptor holds potential therapeutic value in various areas by modulating immune cell activity.
LEUKINE is the only FDA-approved drug targeting the GM-CSF receptor, indicated for 6 conditions since 1991. It is a biologic (other) modality, developed by BERLEX LABS.
Top GM-CSF receptor Drugs
BERLEX LABS is the only company with an approved drug targeting GM-CSF receptor.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
GM-CSF receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GM-CSF receptor, using biologic (other) modality.
Explore opportunities for novel modalities to differentiate from the existing treatment.
GM-CSF receptor Clinical Trials 86 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GM-CSF receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 36 | 25 | 3 | 7 | 89% |
| Phase 2 | 44 | 22 | 6 | 16 | 79% |
| Phase 3 | 5 | 3 | 1 | 1 | 75% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GM-CSF receptor Drug Approval Timeline (1991 - 1991)
The first and most recent drug approval was LEUKINE in 1991.
The approval timeline indicates market saturation; consider combination therapies or new indications.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 47 (8 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GM-CSF receptor. A trial counts if an approved drug acting on GM-CSF receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.